Search Results - "Loken, Michael R."

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531 by Lamba, Jatinder K, Chauhan, Lata, Shin, Miyoung, Loken, Michael R, Pollard, Jessica A, Wang, Yi-Cheng, Ries, Rhonda E, Aplenc, Richard, Hirsch, Betsy A, Raimondi, Susana C, Walter, Roland B, Bernstein, Irwin D, Gamis, Alan S, Alonzo, Todd A, Meshinchi, Soheil

“…Purpose Gemtuzumab ozogamicin (GO), a CD33-targeted immunoconjugate, is a re-emerging therapy for acute myeloid leukemia (AML). CD33 single nucleotide…”
Get full text

CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target by Le, Quy, Hadland, Brandon, Smith, Jenny L, Leonti, Amanda, Huang, Benjamin J, Ries, Rhonda, Hylkema, Tiffany A, Castro, Sommer, Tang, Thao T, McKay, Cyd N, Perkins, LaKeisha, Pardo, Laura, Sarthy, Jay, Beckman, Amy K, Williams, Robin, Idemmili, Rhonda, Furlan, Scott, Ishida, Takashi, Call, Lindsey, Srivastava, Shivani, Loeb, Anisha M, Milano, Filippo, Imren, Suzan, Morris, Shelli M, Pakiam, Fiona, Olson, Jim M, Loken, Michael R, Brodersen, Lisa, Riddell, Stanley R, Tarlock, Katherine, Bernstein, Irwin D, Loeb, Keith R, Meshinchi, Soheil

“…The CBFA2T3-GLIS2 (C/G) fusion is a product of a cryptic translocation primarily seen in infants and early childhood and is associated with dismal outcome…”
Get full text

NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report by Ostronoff, Fabiana, Othus, Megan, Gerbing, Robert B., Loken, Michael R., Raimondi, Susana C., Hirsch, Betsy A., Lange, Beverly J., Petersdorf, Stephen, Radich, Jerald, Appelbaum, Frederick R., Gamis, Alan S., Alonzo, Todd A., Meshinchi, Soheil

“…NUP98/NSD1 has recently been reported in association with poor outcome in acute myeloid leukemia (AML). Previous studies also observed a high overlap between…”
Get full text

Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study by Smith, Jenny L, Ries, Rhonda E, Hylkema, Tiffany, Alonzo, Todd A, Gerbing, Robert B, Santaguida, Marianne T, Eidenschink Brodersen, Lisa, Pardo, Laura, Cummings, Carrie L, Loeb, Keith R, Le, Quy, Imren, Suzan, Leonti, Amanda R, Gamis, Alan S, Aplenc, Richard, Kolb, E Anders, Farrar, Jason E, Triche, Jr, Timothy J, Nguyen, Cu, Meerzaman, Daoud, Loken, Michael R, Oehler, Vivian G, Bolouri, Hamid, Meshinchi, Soheil

“…A cryptic inv(16)(p13.3q24.3) encoding the fusion is associated with poor outcome in infants with acute megakaryocytic leukemia. We aimed to broaden our…”
Get full text

Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group by Tarlock, Katherine, Alonzo, Todd A, Gerbing, Robert B, Raimondi, Susana C, Hirsch, Betsy A, Sung, Lillian, Pollard, Jessica A, Aplenc, Richard, Loken, Michael R, Gamis, Alan S, Meshinchi, Soheil

“…Gemtuzumab ozogamicin (GO), a calicheamicin-conjugated mAb against CD33, has been used in the treatment of acute myeloid leukemia (AML). We evaluated the…”
Get full text

CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children's Oncology Group by Menssen, Andrew J, Hudson, Chad A, Alonzo, Todd, Gerbing, Robert, Pardo, Laura, Leonti, Amanda, Cook, Jacqueline A, Hsu, Fan-Chi, Lott, Loren L, Dai, Fangyan, Fearing, Collette, Ghirardelli, Keely, Hylkema, Tiffany, Tarlock, Katherine, Loeb, Keith R, Kolb, Edward A, Cooper, Todd, Pollard, Jessica, Wells, Denise A, Loken, Michael R, Aplenc, Richard, Meshinchi, Soheil, Brodersen, Lisa Eidenschink

“…As curative therapies for pediatric AML remain elusive, identifying potential new treatment targets is vital. We assessed the cell surface expression of CD74,…”
Get full text

Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531 by Voigt, Andrew P, Brodersen, Lisa Eidenschink, Alonzo, Todd A, Gerbing, Robert B, Menssen, Andrew J, Wilson, Elisabeth R, Kahwash, Samir, Raimondi, Susana C, Hirsch, Betsy A, Gamis, Alan S, Meshinchi, Soheil, Wells, Denise A, Loken, Michael R

“…Diagnostic biomarkers can be used to determine relapse risk in acute myeloid leukemia, and certain genetic aberrancies have prognostic relevance. A diagnostic…”
Get full text

Consistent quantitative gene product expression: #3. Invariance with age by Loken, Michael, R., Voigt, Andrew P., Eidenschink Brodersen, Lisa, Fritschle, Wayne, Menssen, Andrew J., Wells, Denise A.

“…The quantitative expression of cell surface antigens and light scattering properties of five cellular reference populations in stressed bone marrow specimens…”
Get full text

Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia by SORROR, Mohamed L, MARIS, Michael B, MCSWEENEY, Peter, RADICH, Jerald P, BREDESON, Christopher, BRUNO, Benedetto, LANGSTON, Amelia, LOKEN, Michael R, AL-ALI, Haifa, BLUME, Karl G, STORB, Rainer, MALONEY, David G, SANDMAIER, Brenda M, STORER, Barry E, STUART, Monic J, HEGENBART, Ute, AGURA, Edward, CHAUNCEY, Thomas R, LEIS, Jose, PULSIPHER, Michael

“…Patients with chemotherapy-refractory chronic lymphocytic leukemia (CLL) have a short life expectancy. The aim of this study was to analyze the outcome of…”
Get full text

Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes by Chu, Sung-Chao, Wang, Tso-Fu, Li, Chi-Cheng, Kao, Ruey-Ho, Li, Dian-Kun, Su, Yu-Chieh, Wells, Denise A, Loken, Michael R

“…Abstract The aim of this study is to validate the clinical utility of the flow cytometric scoring system (FCSS), quantifying phenotypic aberrancies in the…”
Get full text

Flow cytometry in myelodysplastic syndromes: Report from a working conference by Loken, Michael R, van de Loosdrecht, Arjan, Ogata, Kiyoyuki, Orfao, Alberto, Wells, Denise A

“…Abstract Since new therapeutic strategies are emerging in myelodysplastic syndromes (MDS), a refined diagnostic procedure of the several subgroups of MDS is of…”
Get full text

Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma by Burnworth, Bettina, PhD, Wang, Zhixing, PhD, Singleton, Timothy P., MD, Bennington, Angela, BS, Fritschle, Wayne, BS, Bennington, Richard, MS, Brodersen, Lisa Eidenschink, PhD, Wells, Denise A., MD, Loken, Michael R., PhD, Zehentner, Barbara K., Dr

“…Highlights • Sorted B- and plasma cells are clonally unrelated in the majority of suspected LPL. • MYD88 L265P is found in both fractions for confirmed WM, but…”
Get full text

High Expression of the Very Late Antigen-4 Integrin Independently Predicts Reduced Risk of Relapse and Improved Outcome in Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group by WALTER, Roland B, ALONZO, Todd A, LOKEN, Michael R, MESHINCHI, Soheil, GERBING, Robert B, HO, Phoenix A, SMITH, Franklin O, RAIMONDI, Susana C, HIRSCH, Betsy A, GAMIS, Alan S, FRANKLIN, Janet L, HURWITZ, Craig A

“…To evaluate the prognostic significance of the integrin cell adhesion molecule very late antigen-4 (VLA-4) in acute myeloid leukemia (AML). We prospectively…”
Get full text

Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3 /ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031 by Pollard, Jessica A, Alonzo, Todd A, Gerbing, Robert, Brown, Patrick, Fox, Elizabeth, Choi, John, Fisher, Brian, Hirsch, Betsy, Kahwash, Samir, Getz, Kelly, Levine, John, Brodersen, Lisa Eidenschink, Loken, Michael R, Raimondi, Susana, Tarlock, Katherine, Wood, Andrew, Sung, Lillian, Kolb, E Anders, Gamis, Alan, Meshinchi, Soheil, Aplenc, Richard

“…High allelic ratio (HAR) /ITD (AR > 0.4) mutations confer poor prognosis in pediatric acute myeloid leukemia (AML). COG AAML1031 studied the feasibility and…”
Get full text

Measuring response to therapy in AML: Difference from normal flow cytometry vs RQ-PCR by Loken, Michael R, Hudson, Chad A

“…Multiple technologies have been used to monitor response to therapy in acute myeloid leukemia (AML) to improve detection of leukemia over the standard of…”
Get full text

Prognostic significance of flow cytometric residual disease, dysregulated neutrophils/monocytes, and hematogones in adult acute myeloid leukemia in first remission by Chu, Sung-Chao, Wang, Tso-Fu, Su, Yu-Chieh, Kao, Ruey-Ho, Wu, Yi-Feng, Li, Dian-Kun, Li, Szu-Chin, Li, Chi-Cheng, Wells, Denise A., Loken, Michael R.

“…Fifty-one consecutive non-M3 acute myeloid leukemia (AML) patients who had achieved morphologic complete remission (mCR) after induction chemotherapy were…”
Get full text

Expression of tumor necrosis factor–related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis by Zang, Dae Young, Goodwin, Ray G., Loken, Michael R., Bryant, Eileen, Deeg, H. Joachim

“…Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL), a member of the tumor necrosis factor (TNF) family, binds to several cell-surface receptors…”
Get full text

CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group by Tarlock, Katherine, Lamble, Adam J., Wang, Yi-Cheng, Gerbing, Robert B., Ries, Rhonda E., Loken, Michael R., Brodersen, Lisa Eidenschink, Pardo, Laura, Leonti, Amanda, Smith, Jenny L., Hylkema, Tiffany A., Woods, William G., Cooper, Todd M., Kolb, E. Anders, Gamis, Alan S., Aplenc, Richard, Alonzo, Todd A., Meshinchi, Soheil

“…Biallelic CEBPA mutations are associated with favorable outcomes in acute myeloid leukemia (AML). We evaluated the clinical and biologic implications of…”
Get full text

Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group by Loken, Michael R., Alonzo, Todd A., Pardo, Laura, Gerbing, Robert B., Raimondi, Susana C., Hirsch, Betsy A., Ho, Phoenix A., Franklin, Janet, Cooper, Todd M., Gamis, Alan S., Meshinchi, Soheil

“…Early response to induction chemotherapy is a predictor of outcome in acute myeloid leukemia (AML). We determined the prevalence and significance of…”
Get full text

CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group by Lamble, Adam J, Eidenschink Brodersen, Lisa, Alonzo, Todd A, Wang, Jim, Pardo, Laura, Sung, Lillian, Cooper, Todd M, Kolb, E Anders, Aplenc, Richard, Tasian, Sarah K, Loken, Michael R, Meshinchi, Soheil

“…Increased CD123 surface expression has been associated with high-risk disease characteristics in adult acute myeloid leukemia (AML), but has not been…”
Get full text